linjc16/ctgov huggingface dataset:
Silicone Tube for the Surgical Treatment of Glaucoma

Study Overview
=================
Brief Summary
-----------------
The biocompatible silicone tube miniature drainage device is a small, non-valved implant to shunt aqueous humor underneath the conjunctiva to control the intraocular pressure. Efficacy and safety were evaluated with a minimum follow-up of 12 months.

Detailed Description
-----------------
Patients were examined postoperatively at 1 day, 1 week, 1, 3, 6, 12, 18, 24 months or more frequent when required. IOP, BCVA and slit lamp biomicroscopy were observed at every visit. History of all medication details and postoperative complications were recorded. One-way analysis of variance (ANOVA) with repeated measures was used to analyze the other differences over time in IOP and BCVA. Nonparametric K-related samples test was used to analyze the difference of medications number at different time points. Success rates were evaluated using Kaplan-Meyer survival analysis curves.

Official Title
-----------------
Silicone Tube Miniature Drainage Device Implanted Under Scleral Flap for the Surgical Treatment of Glaucoma

Conditions
-----------------
Glaucoma, Open-Angle

Intervention / Treatment
-----------------
* Device: silicone tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Eligible patients were at least 18 years of age and presented with medically uncontrolled POAG requiring incisional surgery for IOP (intraocular pressure) reduction. - Exclusion Criteria:Exclusion criteria included narrow angles, normal tension glaucoma, previous eye surgery (except cataract surgery), neovascular glaucoma, uveitis, any ocular abnormality that would preclude accurate IOP assessment, and inability to comply with the follow-up program or unwillingness to participate in this study. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: silicone tube|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP | Intraocular pressure | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of anti-glaucoma medication | Number of anti-glaucoma medication | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
silicone tube, miniature drainage device, POAG, IOP
Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
This is an open-label, non-interventional study to evaluate efficacy and safety in rheumatoid arthritis participants receiving tocilizumab as per the product label.

Official Title
-----------------
Documentation of the Efficacy and Safety of RoActemra in the Treatment of Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: Tocilizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Participants with rheumatoid arthritis receiving tocilizumab as per product label Exclusion Criteria: - No specific exclusion criteria were specified for this non-interventional trial
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rheumatoid arthritis participants<br>Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study. | Drug: Tocilizumab<br>* Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.<br>* Other names: RoActemra;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease Activity Score Based on 28-joints Count (DAS28) |  | Month 12 | 
| Simplified Disease Activity Index (SDAI) Score |  | Month 12 | 
| Clinical Disease Activity Index (CDAI) Score |  | Month 12 | 
| Percentage of Participants Achieving American College of Rheumatology (ACR) Response |  | Month 12 | 
| Tender Joint Count (TJC) |  | Month 12 | 
| Swollen Joint Count (SJC) |  | Month 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants with any Adverse Event (AE) |  | Up to 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rheumatoid arthritis, RoActemra, Tocilizumab
Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference?

Study Overview
=================
Brief Summary
-----------------
Dorsal scapular nerve (DSN) entrapment syndrome is an under-recognized cause of neck and shoulder pain. DSN injuries can be the origin of a well-defined chronic pain syndrome, often referred to as DSN syndrome. DSN syndrome is often characterized by a dull ache along the medial border of the scapula.

Detailed Description
-----------------
Dorsal scapular nerve syndrome typically presents with a weakness of the levator scapulae and the rhomboid muscles, and results in a winged scapula. A winged scapula is where the scapula protrudes from the patient's back and can affect the ability to lift objects or pull and push. The winging of the scapula seen with dorsal scapular nerve syndrome is not as severe as seen as injury or paralysis of the serratus anterior muscle. Dorsal scapular nerve entrapment is a very under-recognized cause of neck and shoulder pain. The scapular winging may be subtle, and the symptoms are easily mistaken for other problems. A careful history and physical exam, along with a high index of suspicion, are necessary for accurate diagnosis and therefore appropriate treatment. Injection of the dorsal scapular nerve under ultrasound guidance can be diagnostic as well as therapeutic.

Official Title
-----------------
Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference?

Conditions
-----------------
Pain, Chronic

Intervention / Treatment
-----------------
* Drug: Depo medrol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: scapular pain Exclusion Criteria: cervical radiculopathy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group I<br>scalene muscle level injection of depomedrol | Drug: Depo medrol<br>* local injection<br>|
| Experimental: Group II<br>Rheumboid muscle level injection of depomedrol | Drug: Depo medrol<br>* local injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| scapular pain | visual analog scale 1-10 | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| movement pain | visual analog scale 1-10 | 3 months | 
| fatigue | disability fatigue score | 3 months |
Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of Kanarb® tablet (fimasartan) in healthy subjects

Official Title
-----------------
Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Fimasartan
* Drug: Fimasartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age: 20 - 55 years body weight: standard weight(Broca's index, Possible range is plus or minus 20percent) written informed consent Exclusion Criteria: known allergy to Fimasartan existing cardiac or hematological diseases existing hepatic and renal diseases existing gastrointestinal diseases acute or chronic diseases which could affect drug absorption or metabolism history of any serious psychological disorder abnormal diet which could affect drug absorption or metabolism positive drug or alcohol screening smokers of 10 or more cigarettes per day participation in a clinical trial during the last 90 days prior to the start of the study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: (R)(T)<br>Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg | Drug: Fimasartan<br>* Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg<br>|
| Active Comparator: (T)(R)<br>Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg | Drug: Fimasartan<br>* Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf, AUC, Cmax, Tmax, half-life; t1/2z, AUCt, Vdss, Cl, |  | PO : 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr, IV : 0.25, 0.5, 0.75, 1, 1.08, 1.17, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fimasartan, absolute bioavailability
Study of Physician Awareness of and Communication About Patient Readmissions to the Hospital

Study Overview
=================
Brief Summary
-----------------
Patients admitted to inpatient medicine services often require early hospital readmission, and often they are readmitted to different physician or team, potentially without the knowledge of the prior physician or team. Thus, physicians may lose the opportunity to share valuable information about readmitted patients, which may be detrimental to continuity of care and patient safety. The purpose of this study is to determine baseline awareness and communication rates among physicians regarding readmissions, and then measure the effect of automatic notification on these rates.

Official Title
-----------------
Physician Awareness of and Communication About Hospital Readmissions

Conditions
-----------------
Hospital Readmission

Intervention / Treatment
-----------------
* Other: Automatic notification of readmissions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to the general medicine service at two academic medical centers, and unexpectedly readmitted within 14 days. Exclusion Criteria: Patients readmitted to the same physician(s), or those whose readmission was planned

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Other: Automatic notification of readmissions<br>* The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.<br>|
| No Intervention: 2<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physician Awareness and Communication Rates |  | Within 24 hours of readmission time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hospital Readmission, Continuity of Care, Quality of Health Care
Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis

Study Overview
=================
Brief Summary
-----------------
Assess the level of lipid mediators in patients with psoriasis Assess the urinary level of biopyrins as New marker of oxidative stress in patients with psoriasis Correlate the serum level of bioactive lipid mediators and urinary level of biopyrins with Psoriasis Area and Severity Index

Detailed Description
-----------------
Psoriasis is acommon immune mediated inflammatory skin disorder of complex pathomechanisms which is generically conditioned and influenced by environmental factors

Official Title
-----------------
Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Diagnostic Test: Serum and urinary assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age from12 to 80 and both sex Exclusion Criteria: patients with other dermatological disorders

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the serum level of bioactive lipid mediators in patients with psoriasis | Bioactive lipid mediators (LMs) are potent compounds reported to play a role in the development and resolution of inflammation. | 1 month |
Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants

Study Overview
=================
Brief Summary
-----------------
VLBW infants are at risk of developing retinopathy of prematurity (ROP). In the first phase of ROP there is a down-regulation of retinal VEGF-expression because of postnatal relative hyperoxia, followed by an upregulation of VEGF mediated through retinal hypoxia, which leads to pathologic vessel formation. VEGF acts through binding to the specific receptor FLT-1, the soluble form sFLT-1 is a specific antagonist of VEGF action. Erythropoietin, given to VLBW infants to prevent anemia, may stimulate VEGF-production in neuronal cells. Currently, there are no data published about VEGF urine-levels in VLBW infants and it is not known, if urine VEGF-levels may serve as a non-invasive marker of ROP-risk. Further shall be investigated, if erythropoietin-therapy increases urine VEGF-levels and if there is a correlation with ROP-development.

Conditions
-----------------
Infant, Very Low Birth Weight

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: gestational age < 32 weeks birth weight <1500g Exclusion Criteria: absent written consent by parents connatal eye malformation

Ages Eligible for Study
-----------------
Maximum Age: 32 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>VLBW infants with erythropoietin therapy | |
| 2<br>VLBW infants without erythropoietin therapy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of ROP |  | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ROP, VLBW, Epo, IUGR, VEGF, sFLT-1, very low birth weight infants, retinopathy of prematurity, erythropoietin therapy and risk of ROP
Application Software in Dosage Adjustment for Advanced Cancer Patients With Pain

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine whether Application (APP) would help clinical doctors to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets in advanced patients with cancer pain.

Official Title
-----------------
Application Software in Dosage Adjustment for Advanced Cancer Patients With Pain

Conditions
-----------------
Pain, Physicians, Oxycodone

Intervention / Treatment
-----------------
* Device: APP software


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a histologically confirmed diagnosis of Cancer or Sarcoma advanced patients with severe cancer pain(score >3) having used or expected to use the Oxycodone Hydrochloride Prolonged-release Tablets Exclusion Criteria: allergic to Oxycodone Hydrochloride Prolonged-release Tablets, or other reasons (determined by clinical doctors) unable to use the Opioids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: APP in dosage adjustment<br>Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain. | Device: APP software<br>* A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numerical Pain Rating Scale |  | upto 8 months |
Early Goal-Directed Therapy Utilizing Transpulmonary Thermodilution and Severe Burn Injury

Study Overview
=================
Brief Summary
-----------------
This study aimed to optimize fluid resuscitation with transpulmonary thermodilution (TPTD)-guided protocol and to lower the mortality rate of the severely burned.

Official Title
-----------------
Early Goal-Directed Therapy Utilizing Transpulmonary Thermodilution for Treating Adult Patients With Severe Burn Injury

Conditions
-----------------
Burns

Intervention / Treatment
-----------------
* Other: Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.
* Other: Study group: TPTD device was implemented for monitoring.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (age > 18 years). Major burn (as total burned surface area (TBSA) > 20% with at least second degree burn depth). Admitted to the intensive care unit (ICU) of the Burn Center. Exclusion Criteria: Patients younger than 18 years old. Patients with severe cardiopulmonary diseases, or associated with other major trauma. Patient with incomplete data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with major burn.<br>Adult patients (age > 18 years) suffered from major burn which defined as total burned surface area (TBSA) > 20% with at least second degree burn depth were admitted to the intensive care unit (ICU) of the Burn Center at a tertiary medical center were retrospectively reviewed. | Other: Control group: Patients being admitted when The advancement of transpulmonary thermodilution(TPTD) device was unavailable.<br>* The control group included patients being admitted when TPTD device was unavailable; and relatively stable patients without the need for TPTD. The adequacy of fluid resuscitation in the control group was monitored by traditional monitoring parameters including vital signs and hourly urine output.<br>Other: Study group: TPTD device was implemented for monitoring.<br>* TPTD device was implemented for monitoring; the inclusion criteria included patients suffering from 2nd degree burn greater than 40% TBSA; a combined 2nd to 3rd degree burn greater than 30% TBSA; or patients with inhalation injury despite the burned surface area.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient mortality | The primary outcome was patient mortality after major burn. | Up to 6 months |